Checkers
Two points of clarification:
1) Delaying until after IND approval from FDA and trial parameters are known resolves a couple of risk factors, but certainly does not eliminate risk totally. There remains the very substantial risk around a successful Phase III trial which one poster today has indicated might have an approx 20% probability of success.
2) Don't agree with your analysis that Orphan Drug status is a nice to have but not essential. PRR NEEDS the market exclusivity period that orphan status provides. The patent life just isn't long enough without it. That said, I FULLY EXPECT that they will get orphan status as ovarian cancer seems to fit squarely within the parameters and others have been awarded orphan designation in the space. However, I would not expect PRR to rerate on the back of Orphan designation as it is effectively a given and not itself a risk.
Cheers
Red.
- Forums
- ASX - By Stock
- IMM
- buyers building
buyers building, page-34
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
33.5¢ |
Change
0.015(4.69%) |
Mkt cap ! $486.6M |
Open | High | Low | Value | Volume |
32.0¢ | 33.5¢ | 32.0¢ | $1.303M | 3.974M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 29843 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
33.5¢ | 105523 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 29843 | 0.330 |
4 | 35190 | 0.325 |
6 | 82430 | 0.320 |
2 | 79615 | 0.315 |
5 | 54791 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.335 | 105523 | 4 |
0.340 | 51705 | 5 |
0.345 | 169207 | 6 |
0.350 | 97759 | 7 |
0.355 | 100000 | 1 |
Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |